Stocklytics score rationale: value 56, quality 22, growth 20.
Financials
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
5421613
3722000
3479000
2541000
2325000
2647000
4776000
36208000
-7190000
29643000
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and…
Forecast
Consensus Buy from 5 analysts. Average price target $38.00, +14.0% versus the current price. Low $30.00. High $46.00.
Analysts have an average 12-month price target of $38.00 for Nanobiotix (NBTX), 14.1% above the current price of $33.30. Of 5 analysts covering the stock, 4 rate it Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
NBTX price target
12-month price target
Low
$30.00
Average
$38.00
High
$46.00
The average is 14.1% above the current price of $33.30.
Is Nanobiotix a buy or sell?
Of 5 analysts, 4 rate Nanobiotix Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
The Stocklytics Score for NBTX is 33 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
NBTX forecast FAQs
What is the NBTX price target?
$38.00 average, with a published range of $30.00 to $46.00.
Is Nanobiotix a buy or sell?
The consensus is Buy from 5 analysts. This is not a recommendation.
What is the Nanobiotix stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -0.53. The average revenue estimate is $25.47 million.
What will NBTX be worth in 2030?
No reliable forecast exists that far out.
When is Nanobiotix's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.